Trial Profile
Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 09 Sep 2021 Results published in the Blood
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 Planned End Date changed from 1 Jan 2019 to 31 Dec 2021.